Your SlideShare is downloading. ×
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Cell therapy in cardiovascular diseases
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Cell therapy in cardiovascular diseases

3,192

Published on

stem cell therapy and cell therapy is a new emerging way in medicine and in cardiovascular diseases.

stem cell therapy and cell therapy is a new emerging way in medicine and in cardiovascular diseases.

Published in: Health & Medicine, Technology
0 Comments
3 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
3,192
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
281
Comments
0
Likes
3
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1.
  • 2. Cell Therapy For Cardiovascular Diseases
  • 3. Supervisors:
    Prof. Dr.
    Ahmed Mohamed ZaghlolDarwish
    Professor of Cardiology
    Faculty of Medicine
    Tanta University 
    Prof. Dr.
    Magdy Mohamed El-Masry
    Professor of Cardiology
    Faculty of Medicine
    Tanta University 
    Prof. Dr.
    SamiaMahmoudSharf El-deen
    Professor of Cardiology
    Faculty of Medicine
    Tanta University
  • 4. Definitions
  • 5. Definition:
    • Stem cells:
    Cells with 3 major criteria:
    • Self renewal.
    • 6. Capacity of clonal expansion.
    • 7. Multipotant differentiation.
    .
  • 8. Definition:
    • Progenitor cells:
    • 9. Can differentiate into a specific type of cells.
    • 10. But, they are more specific than stem cells: they are pushed to differentiate into their "target" cells.
  • Classification of cells according to their potency
  • 11. Classification of cells according to their potency:
    Totipotent stem cells:
    • Produce all types of tissue including placenta.
    • 12. Eg. Early embryonic cells.
    Pleuripotent stem cells :
    • Produce all types of tissue except placenta.
    • 13. EG. (ESCs).
  • Classification of cells according to their potency:
    Multipotent stem cells:
    • Produce cells of a closely related family .
    • 14. Eg. (HSCs) that differentiate to red blood cells, white blood cells and platelets.
    Unipotent stem cells :
    • Produce only one type of cells and have the ability of self renewal.
    • 15. Eg. epidermal stem cells.
  • Classification of cells according to their source.
  • 16. Classification of cells according to their source:
    • Embryonic Stem Cells.
    • 17. Bone Marrow–Derived Stem/Progenitor Cells:
    • 18. Hematopoietic stem cells (HSCs).
    • 19. Mesenchymal (stromal) stem cells (MSCs).
    • 20. Endothelial progenitor cells.
    • 21. Umbilical Cord Blood Cells.
    • 22. Resident cardiac stem/progenitor cells.
    • 23. Adipose-derived stem cells.
    • 24. Skeletal myoblasts.
    • Embryonic Stem Cells.
    • 25. Bone Marrow–Derived Stem/Progenitor Cells:
    • 26. Hematopoietic stem cells (HSCs).
    • 27. Mesenchymal (stromal) stem cells (MSCs).
    • 28. Endothelial progenitor cells.
    • 29. Umbilical Cord Blood Cells.
    • 30. Resident cardiac stem/progenitor cells.
    • 31. Adipose-derived stem cells.
    • 32. Skeletal myoblasts.
  • Embryonic Stem Cells.
    • Are isolated from the inner cell mass of the blastocyst.
    • Embryonic Stem Cells.
    • 33. Bone Marrow–Derived Stem/Progenitor Cells:
    • 34. Hematopoietic stem cells (HSCs).
    • 35. Mesenchymal (stromal) stem cells (MSCs).
    • 36. Endothelial progenitor cells.
    • 37. Umbilical Cord Blood Cells.
    • 38. Resident cardiac stem/progenitor cells.
    • 39. Adipose-derived stem cells.
    • 40. Skeletal myoblasts.
  • Bone Marrow–Derived Stem/ Progenitor Cells
  • 41.
    • Embryonic Stem Cells.
    • 42. Bone Marrow–Derived Stem/Progenitor Cells:
    • 43. Hematopoietic stem cells (HSCs).
    • 44. Mesenchymal (stromal) stem cells (MSCs).
    • 45. Endothelial progenitor cells.
    • 46. Umbilical Cord Blood Cells.
    • 47. Resident cardiac stem/progenitor cells.
    • 48. Adipose-derived stem cells.
    • 49. Skeletal myoblasts.
  • Hematopoietic stem cells
    Sources :
    Umbilical cord blood (1 per 1 million nucleated cell).
    Adult bone marrow (1 per 3 million nucleated cell).
    Mobilized peripheral blood (1 per 6 million nucleated cell).
    • Capable of unlimited cell proliferation in bone marrow producing mature blood cells.
    • Embryonic Stem Cells.
    • 50. Bone Marrow–Derived Stem/Progenitor Cells:
    • 51. Hematopoietic stem cells (HSCs).
    • 52. Mesenchymal (stromal) stem cells (MSCs).
    • 53. Endothelial progenitor cells.
    • 54. Umbilical Cord Blood Cells.
    • 55. Resident cardiac stem/progenitor cells.
    • 56. Adipose-derived stem cells.
    • 57. Skeletal myoblasts.
  • Mesenchymal (stromal) stem cells:
    Present as a rare population of cells in bone marrow (0.001% to 0.01% of the nucleated cells).
    Other sources of MSC including placenta, adipose tissue, cord blood and liver.
    They can be cloned and expanded in vitro more than 1 million-fold and retain the ability to differentiate to several cells of mesodermal origin.
  • 58.
    • Embryonic Stem Cells.
    • 59. Bone Marrow–Derived Stem/Progenitor Cells:
    • 60. Hematopoietic stem cells (HSCs).
    • 61. Mesenchymal (stromal) stem cells (MSCs).
    • 62. Endothelial progenitor cells.
    • 63. Umbilical Cord Blood Cells.
    • 64. Resident cardiac stem/progenitor cells.
    • 65. Adipose-derived stem cells.
    • 66. Skeletal myoblasts.
  • Endothelial progenitor cells.
    Cells can give rise to endothelial cells and contribute to endothelial recovery and new capillary formation after ischemia.
    Sources of endothelial progenitorcells:
    Bone marrow-derived EPCs.
    Non Bone marrow-derived EPCs:
    Which arise from Various tissues, including adipose tissue, neuronal tissue, and the heart itself.
  • 67.
    • Embryonic Stem Cells.
    • 68. Bone Marrow–Derived Stem/Progenitor Cells:
    • 69. Hematopoietic stem cells (HSCs).
    • 70. Mesenchymal (stromal) stem cells (MSCs).
    • 71. Endothelial progenitor cells.
    • 72. Umbilical Cord Blood Cells.
    • 73. Resident cardiac stem/progenitor cells.
    • 74. Adipose-derived stem cells.
    • 75. Skeletal myoblasts.
  • Umbilical Cord Blood Cells.
    Perfect source for cell-based therapy as they are rich in both stem and progenitor cells.
    No ethical limitations regarding its use.
    No risks to the mother or to the newborn in collecting the cells after labor.
    There are many public and private UCB banks worldwide with cells readily available for transplantation at the most optimal time.
  • 76.
    • Embryonic Stem Cells.
    • 77. Bone Marrow–Derived Stem/Progenitor Cells:
    • 78. Hematopoietic stem cells (HSCs).
    • 79. Mesenchymal (stromal) stem cells (MSCs).
    • 80. Endothelial progenitor cells.
    • 81. Umbilical Cord Blood Cells.
    • 82. Resident cardiac stem/progenitor cells.
    • 83. Adipose-derived stem cells.
    • 84. Skeletal myoblasts.
  • Resident cardiac stem/progenitor cells.
    • Recently it was proven that adult heart is an organ with regeneration capacity.
    • 85. This regeneration capacity are likely due to presence of defined pool of resident progenitor cells.
    • 86. These cells are responsible for the normal turnover of cardiomyocytes during physiologic growth and aging.
  • Resident cardiac stem/progenitor cells.
    • Resident cardiac stem/ progenitor cells have 4 populations according to their cell marker:
    Cardiac side population (SP) cells.
    c-kit positive cardiac stem cells.
    Sca-1 positive cardiac progenitor cells.
    Cardiosphere-derived cardiac stem cells
  • 87.
    • Embryonic Stem Cells.
    • 88. Bone Marrow–Derived Stem/Progenitor Cells:
    • 89. Hematopoietic stem cells (HSCs).
    • 90. Mesenchymal (stromal) stem cells (MSCs).
    • 91. Endothelial progenitor cells.
    • 92. Umbilical Cord Blood Cells.
    • 93. Resident cardiac stem/progenitor cells.
    • 94. Adipose-derived stem cells.
    • 95. Skeletal myoblasts.
  • Adipose-derived stem cells.
    Recent studies have suggested that stem cells are present within the adipose tissue.
    This Adipose-derived stem cells, like MSCs, have the ability to differentiate toward the osteogenic, adipogenic, myogenic, chondrogenic and neurogenic cells.
    The ease of access to fat and its abundance makes adipose tissue a potentially useful source of stem cells for clinical applications.
  • 96.
    • Embryonic Stem Cells.
    • 97. Bone Marrow–Derived Stem/Progenitor Cells:
    • 98. Hematopoietic stem cells (HSCs).
    • 99. Mesenchymal (stromal) stem cells (MSCs).
    • 100. Endothelial progenitor cells.
    • 101. Umbilical Cord Blood Cells.
    • 102. Resident cardiac stem/progenitor cells.
    • 103. Adipose-derived stem cells.
    • 104. Skeletal myoblasts.
  • Skeletal myoblasts.
    Skeletal myoblasts were the first candidates for cardiac repair.
    They are derived from skeletal muscles “satellite cells”.
    They are responsible for regeneration of damaged skeletal muscle after injury.
  • 105. Methods Of Cell Delivery
  • 106. The ideal modality of cell delivery should have the following characteristics:
    • Safe with minimal complications.
    • 107. Easily performed.
    • 108. Cost benefit ratio within range.
    • 109. Applicable across a wide range of clinical scenarios
    • 110. Targeting of the cells precisely in an adequate cardiac environment.
  • Direct myocardial injection:
    • The most accurate type of delivery that can be achieved by direct visualization during thoracotomy.
    • 111. Can be done either as an adjunct to CABG or as sole therapy.
  • Disadvantages:
    • Possible arrhythmogenicity.
    • 112. Need for concomitant open-heart surgery.
    • 113. Can’t be repeated if needed.
  • Transcatheterendomyocardial injection:
    • Less invasive technique.
    • 114. Electromechanical testing to confirm the presence of ischemic or dead myocardium should be done before cell delivery.
  • Disadvantages:
    • Complex procedure as electromechanical map of the left ventricular chamber is required.
  • Intracoronary cell injection:
    • Most popular mode of cell delivery especially after AMI.
    • 115. It can be performed at the same time of (PCI).
    • 116. Disadvantages:
    Not suitable for all cell
    types as larger cells as MSCs
    may occlude the
    Microcirculation.
  • 117.
  • 118. Intravenous injection:
    • The simplest and least invasive delivery route and produces minimal complications.
    • 119. Can easily be repeated if necessary.
    • 120. Disadvantage:
    low percentage of cells delivered.
  • 121. Intramyocardial injection via coronary vein
    • The catheter can enter the coronary sinus directed by IVUS.
    • 122. The needle is directed toward the myocardium through which cells and drugs can be injected.
    • 123. The safety and feasibility of this new catheter approach needs to be investigated.
  • Mechanisms of Myocardial Repair
  • 124. Cell therapy seems to act through three mechanistic pathways:
    Differentiation into cardiomyocytes.
    Cell Fusion with host cardiomyocytes.
    Paracrine effects.
  • 125. Differentiation into cardiomyocytes
    • The cell differentiation to cardiomyocytes is influenced by:
    • 126. high level of circulating stem cells.
    • 127. Organ damage
    • 128. Signaling factors as G-CSF, VEGF.
    • 129. cell-to-cell contact with cardiomyocytes.
    • 130. Doubt still exists if the trasdifferentiated cells can participate in the actively contractile myocardium.
  • Cell Fusion with host cardiomyocytes.
    • Myocardial regeneration could result from fusion of the transplanted stem cell with existing cardiac cells “hybrid cells”.
    • 131. Donor cell genes may compensate for the lost genetic material from the host nucleus during ischemic injury.
  • Paracrine effects:
    • Implanted cells releases a number of local cytokines and growth factors as TNF-α, VEGF, IGF, Cardiotrophin-1.
    • 132. These factors:
    Inhibit cardiomyocyte apoptosis.
    Enhance angiogenesis.
    Rescue injured myocytes.
    Inhibit pathologic remodeling.
  • 133. Cell Therapy for Acute Myocardial Infarction
  • 134.
    • Most of the clinical trials in the field of AMI used BMCs with Conflicting Results.
    • 135. MSCs was used in one trail by Chen et al,
    With significant improvement of LVEF and LVEDd.
    • Further larger randomized trails is needed in this field.
  • 136.
  • 137. Cell Therapy in End-stage Ischemic Heart Disease With no Further Revascularization Options
  • 138.
    • The main therapeutic goal for these patients is to improve blood supply.
    • 139. Most trials have been small phase 1 studies and shown improved perfusion and myocardial function.
    • 140. Concerns were raised by observation that some patient developed an acute coronary syndrome and fatal myocardial infarction.
  • Cell Therapy For Ischemic Cardiomyopathy & Chronic Heart Failure
  • 141.
    • In the field of heart failure results of initial attempts of cell therapy have been more heterogeneous.
    • 142. Two main cells was involved in HF cell therapy trials:
    • 143. Skeletal Myoblasts.
    • 144. Bone Marrow Cells.
  • Skeletal Myoblasts clinical trails:
    • In most trials, improvements of regional wall motion and global LVEF have been noted after myoblast injections.
    • 145. However, myoblast injections increase the risk of ventricular arrhythmias in this patient, with unclear mechanisms.
  • Bone Marrow Cells clinical trails:
    • In most BMCs trials showed improved cardiac function with less complications compared with SKMB trials.
  • Cell Therapy For Pulmonary Arterial Hypertension
  • 146.
    • One of the more recent applications of cell therapy with very limited clinical experience.
    • 147. Role of cell therapy in PAH either:
    • 148. Contributing to blood vessel thickening (remodeling) and blockage in PAH.
    • 149. Repair damaged blood vessels and restore more normal blood flow in the lung.
  • Cell Therapy For Peripheral Vascular disease
  • 150.
    • Cell therapy can induce new vessels formation by 2 mechanisms:
    Vasculogenic effect: by incorporation into newly forming vessels.
    Trophic effect: delivering angiogenic growth factors.
    • Overall, clinical trials reported encouraging effect of cell therapy in this field.
  • Drawbacks to Cell Therapy in Cardiovascular Diseases
  • 151.
    • Cellular therapy has both theoretical and reported safety concerns.
    • 152. These adverse effects include:
  • Atherosclerosis:
    • Neointimal hyperplasia due to excessive accumulation of SMCs derived from donor cells.
    Post-stentingRestenosis:
    • Caused by differentiation of progenitor cells into SMCs within the stented segment
  • G-CSF Induced Acute Coronary Syndromes:
    • Possible due to increased CRP level might induce plaque destabilization and rupture.
    Arrhythmogenesis:
    • A common adverse effect with SKMB trafustion.
    • 153. May be due to the ability of myoblasts to fire action potentials that may induce deleterious extrasystoles
  • Stem Cell Immunogenicity:
    • Allogenic origin of cells has raised concern of allograft rejection and the need for immunosuppressive agents.
    Tumorigenesis:
    • The pluripotency of ESCs may enhance undefined growth in vivo, giving rise to teratomas.
  • Stem Cell Metastasis:
    • Also transplanted ESCs can form teratomas in distant sites such as the submandible and femur.
    Ethical concerns:
    • Regarding ESCs use as they are isolated from the early embryo “destroying the embryo”
  • 154. Thank you

×